810 results match your criteria Pityriasis Rosea

Impact of COVID-19 on Clinicopathological Spectrum of Pityriasis Rosea in Korea.

J Korean Med Sci 2022 Jun 20;37(24):e190. Epub 2022 Jun 20.

Department of Dermatology, Korea University College of Medicine, Seoul, Korea.

Background: Pityriasis rosea (PR) is a papulosquamous eruption with generally unknown origin but suspected to be related to viral etiologies. The clinicopathological spectrum of several disorders with viral etiologies has been altered after the coronavirus disease 2019 (COVID-19) pandemic. The author group could experience coherent histological alterations in PR after the COVID-19 pandemic. Read More

View Article and Full-Text PDF

Cutaneous manifestations following COVID-19 vaccination: A report of 25 cases.

Dermatol Ther 2022 Jun 18:e15651. Epub 2022 Jun 18.

Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Background: Various adverse effects particularly cutaneous manifestations associated with different COVID-19 vaccines have been observed in practice.

Aim: To evaluate all patients who presented to our tertiary center with skin manifestations following COVID-19 vaccines injection from September to December 2021.

Method: All patients with skin manifestation within 30 days or less following COVID-19 vaccination were enrolled in our case-series. Read More

View Article and Full-Text PDF

Six cases of pityriasis rosea following SARS-CoV-2 vaccination with BNT162b2.

J Dtsch Dermatol Ges 2022 Jun 14. Epub 2022 Jun 14.

Department of Dermatology, Hadassah Medical Center, Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel.

View Article and Full-Text PDF

Molecular study of recent virus and its relationship to Pityriasis rosea.

J Popul Ther Clin Pharmacol 2022 8;29(1):e109-e115. Epub 2022 Apr 8.

Department of Dermatology, College of Medicine, University of Thi-Qar, Iraq;

Background: A new type of coronavirus family severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) that has been detected in individuals with several clinical symptoms named COVID-19, was recognized as a pandemic on March 11, 2020. Numerous researches have been conducted on the manifestations of a skin disease related to COVID-19, i.e. Read More

View Article and Full-Text PDF

Coronavirus disease 2019 and pityriasis rosea: A review of the immunological connection.

J Dermatol 2022 Jun 8. Epub 2022 Jun 8.

School and Operative Unit of Allergy and Clinical Immunology, University of Messina, Messina, Italy.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by the activation of a cytokine storm derived from an excess release of cytokine (interleukin [IL]-6, interferon [IFN] I, C-X-C motif chemokine ligand [CXCL]10, tumor necrosis factor [TNF]-α, macrophage inflammatory protein [MIP]1) due to an uncontrolled immune activation. There has been a fivefold increase in the number of cases of pityriasis rosea during the SARS-CoV-2 pandemic. Using the keywords "pityriasis" and "COVID-19", we carried out a PubMed search, including all articles in the English language published until November 2021. Read More

View Article and Full-Text PDF

Prevalence of pityriasis rosea in the United States: A cross-sectional study using the database.

JAAD Int 2022 Sep 19;8:45-46. Epub 2022 May 19.

Department of Dermatology, Perelman School of Medicine, Philadelphia, Pennsylvania.

View Article and Full-Text PDF
September 2022

Pityriasis rosea in pregnancy: A case series and literature review.

J Dtsch Dermatol Ges 2022 May 26. Epub 2022 May 26.

Department of Dermatology and Venereology, Medical University of Graz, Austria.

Background And Objective: Pityriasis rosea (PR), a common skin disease in young adults, may adversely affects the course of pregnancy and the unborn child.

Patients And Methods: Data from forty-six pregnant women with PR seen in the dermatological university clinic between 2003 and 2018 were analyzed and compared with patient data (n = 53) from previously published studies to determine the incidence and risk factors for an unfavorable pregnancy outcome after PR infection.

Results: Unfavorable pregnancy outcomes (defined as miscarriage, preterm delivery before week 37 of gestation, or birth weight < 2,500 g) were significantly less frequent in our study population than in a pooled cohort obtained from previously published studies (10. Read More

View Article and Full-Text PDF

Pityriasis rosea, human herpesvirus 6 infection and pregnancy.

J Med Virol 2022 May 12. Epub 2022 May 12.

Department of Medical Specialities, Dermatology Unit, Ospedale Policlinico San Martino, Genoa, Italy.

View Article and Full-Text PDF

Pityriasis Rosea and Pityriasis Rosea-Like Eruptions after COVID-19 vaccines.

JAAD Int 2022 May 3. Epub 2022 May 3.

Dermatology Unit, San Martino Hospital, Largo R. Benzi, 10, 16132, Genoa, Italy.

View Article and Full-Text PDF

Inverse pityriasis rosea secondary to COVID-19 vaccination.

Proc (Bayl Univ Med Cent) 2022 9;35(3):342-343. Epub 2022 Mar 9.

Department of Dermatology, Texas Tech University Health Sciences Center, Lubbock, Texas.

A 56-year-old woman presented for evaluation of a pruritic rash with associated body aches, fever, and chills that first appeared about 1 week after Johnson and Johnson COVID-19 vaccination. The rash initially presented as one lesion on her left breast that then spread to her face and groin. Based on clinical presentation, dermoscopic findings, and histopathological examination, a diagnosis of inverse pityriasis rosea was made. Read More

View Article and Full-Text PDF

Domperidone-induced pityriasis rosea-like drug eruption.

Clin Case Rep 2022 Apr 5;10(4):e05674. Epub 2022 Apr 5.

Department of Dermatology Farhat Hached university hospital Sousse Tunisia.

Pityriasis rosea is a common, acute, self limiting inflammatory skin disease. Pityriasis rosea-like eruptions (PR-LE) have been reported after drugs. The clinical presentation of PR-LE can be distinguished from pityriasis rosea. Read More

View Article and Full-Text PDF

Thiol-Disulfide Homeostasis in Skin Diseases.

J Clin Med 2022 Mar 9;11(6). Epub 2022 Mar 9.

Department of Dermatology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Oxidative stress represents the imbalance between oxidants and antioxidants and has been associated with a wide range of diseases. Thiols are the most important compounds in antioxidant defense. There is an equilibrium between thiols and their oxidized forms, disulfides, known as dynamic thiol-disulfide homeostasis (TDH). Read More

View Article and Full-Text PDF

A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.

Dermatol Ther 2022 Jun 11;35(6):e15461. Epub 2022 Apr 11.

Department of Dermatology, Rasool Akram Medical Complex Clinical Research Development Center (RCRDC), School of Medicine, Iran University of Medical Sciences, Tehran, Iran.

With dermatologic side effects being fairly prevalent following vaccination against COVID-19, and the multitude of studies aiming to report and analyze these adverse events, the need for an extensive investigation on previous studies seemed urgent, in order to provide a thorough body of information about these post-COVID-19 immunization mucocutaneous reactions. To achieve this goal, a comprehensive electronic search was performed through the international databases including Medline (PubMed), Scopus, Cochrane, Web of science, and Google scholar on July 12, 2021, and all articles regarding mucocutaneous manifestations and considerations after COVID-19 vaccine administration were retrieved using the following keywords: COVID-19 vaccine, dermatology considerations and mucocutaneous manifestations. A total of 917 records were retrieved and a final number of 180 articles were included in data extraction. Read More

View Article and Full-Text PDF

Reduction in new pityriasis rosea diagnoses during the COVID-19 pandemic: Evidence in support of a viral etiology.

JAAD Int 2022 Jun 17;7:124-125. Epub 2022 Mar 17.

Department of Dermatology, George Washington University, Washington, District of Columbia.

View Article and Full-Text PDF

Pityriasis Rosea Induced by COVID-19 Vaccination.

Eur J Case Rep Intern Med 2022 3;9(2):003164. Epub 2022 Feb 3.

Medical School, University of Cyprus, Nicosia, Cyprus.

It is increasingly recognized that SARS-CoV-2 infection and COVID-19 vaccines have been associated with skin disorders, including pityriasis rosea. It has been reported that pityriasis rosea has been triggered by several vaccines, as a rare side-effect. We present two cases of COVID-19 vaccine-induced pityriasis rosea. Read More

View Article and Full-Text PDF
February 2022

Pityriasis rosea during COVID-19: Pathogenesis, diagnosis, and treatment.

J Med Virol 2022 Jul 6;94(7):2915-2916. Epub 2022 Mar 6.

Dermatology Unit, Ospedale Policlinico San Martino, Genoa, Italy.

View Article and Full-Text PDF

Cutaneous adverse reactions of COVID-19 vaccines: A systematic review.

Dermatol Ther 2022 May 8;35(5):e15391. Epub 2022 Mar 8.

Department of Midwifery, Faculty of Nursing and Midwifery, Kermanshah University of Medical Sciences (KUMS), Kermanshah, Iran.

Numerous vaccines are under clinical development and implementation for the prevention of severe course and lethal outcomes of coronavirus disease 2019 (COVID-19). This systematic review aims to summarize and integrated the findings of studies regarding cutaneous side effects of COVID-19 vaccines. This systematic review conducted by searching the scientific databases of PubMed, Scopus, Science direct, and Web of knowledge from the beginning of the COVID-19 to May 10, 2021. Read More

View Article and Full-Text PDF

Cutaneous reactions to COVID-19 vaccines: A review.

JAAD Int 2022 Jun 17;7:178-186. Epub 2022 Feb 17.

Department of Dermatology, Singapore General Hospital, Singapore.

Background: The increasing number of reports on cutaneous reactions following COVID-19 vaccination has led to growing concerns among certain groups.

Objective: We reviewed the published reports of cutaneous lesions after COVID-19 vaccination.

Methods: We conducted a literature search for original and review articles published between January 1, 2020, and September 27, 2021. Read More

View Article and Full-Text PDF

Pattern of Papulosquamous Disorders in Children: A Clinico-Epidemiological Study.

Cureus 2022 Jan 13;14(1):e21194. Epub 2022 Jan 13.

Department of Dermatology, LN Medical College, Bhopal, IND.

Introduction Skin disorders are a major health problem in the pediatric age group and are associated with significant morbidity. Papulosquamous disorders, forming a major part of the skin diseases in children, present in a variety of clinical pattern. This study is conducted in order to study the hospital-based prevalence of papulosquamous disorders in the pediatric age group (2-14 years) and to determine the morphology and clinical patterns with respect to their age and sex distribution. Read More

View Article and Full-Text PDF
January 2022

Pityriasis Rosea Associated With COVID-19 Vaccination: A Common Rash Following Administration of a Novel Vaccine.

Cutis 2021 Dec;108(6):317-318

Department of Dermatology, Beaumont Hospital Farmington Hills, Michigan.

Pityriasis rosea is a common, self-limited, papulosquamous eruption, classically presenting along the Langer lines of the skin. We report a clinically typical case of pityriasis rosea that developed following COVID-19 vaccination. As the novel COVID-19 vaccine becomes more widely available during the ongoing COVID-19 pandemic, it is imperative for both patients and clinicians to be aware of its association with the onset of this benign cutaneous eruption. Read More

View Article and Full-Text PDF
December 2021

Pityriasis rosea-like rash after messenger RNA COVID-19 vaccination: A case report and review of the literature.

JAAD Int 2022 Jun 9;7:164-168. Epub 2022 Feb 9.

Department of Dermatology, The University of Texas Health Science Center, Houston, Texas.

A spectrum of cutaneous reactions to SARs-CoV-2 (COVID-19) vaccines have been reported in the literature. We present a case of a pityriasis rosea-like rash occurring after Pfizer COVID-19 vaccination and review cases of pityriasis rosea (PR)/PR-like eruption (PR-LE) after mRNA COVID-19 vaccine published in the medical literature. Of the 30 cases found, none experienced severe adverse effects and the rash resolved in an average of 5. Read More

View Article and Full-Text PDF

SARS-CoV-2 vaccine-related cutaneous manifestations: a systematic review.

Int J Dermatol 2022 Feb 9. Epub 2022 Feb 9.

Dermatology Clinic, Maggiore Hospital of Trieste, Trieste, Italy.

To date, over 250 million people have been reportedly infected by COVID-19 disease, which has spread across the globe and led to approximately 5.1 million fatalities. To prevent both COVID-19 and viral transmission, DNA-based/RNA-based vaccines, non-replicating viral vector vaccines, and inactivated vaccines have been recently developed. Read More

View Article and Full-Text PDF
February 2022

Comment on "Pityriasis rosea in a COVID-19 Pediatric Patient".

Actas Dermosifiliogr 2022 Jan 3;113(1):113-114. Epub 2022 Feb 3.

Dermatology Unit, Ospedale Policlinico San Martino, Largo Rosanna Benzi, Genoa, Italy.

View Article and Full-Text PDF
January 2022

CD123 immunoexpression in cutaneous lupus erythematosus, polymorphous light eruption, pityriasis rosea, and mycosis fungoides.

Postepy Dermatol Alergol 2021 Dec 7;38(6):994-1000. Epub 2022 Jan 7.

Department of Pathology, Duzce University, School of Medicine, Duzce, Turkey.

Introduction: CD123-positive plasmacytoid dendrocytes are prominent in the infiltrate of cutaneous lupus erythematous.

Aim: To determine the significance of the CD123 immunostain, which labels plasmacytoid dendritic cells (PDC), in cutaneous lupus erythematous (CLE), polymorphous light eruption (PLE), pityriasis rosea (PR) and mycosis fungoides (MF).

Material And Methods: A total of 76 cases, including MF ( = 27), CLE ( = 19), PR ( = 19), and PLE ( = 11), were included in the study after reviewing their diagnostic clinical features and pathologic findings. Read More

View Article and Full-Text PDF
December 2021

Pityriasis rosea, pityriasis rosea-like eruptions, and herpes zoster in the setting of COVID-19 and COVID-19 vaccination.

Clin Dermatol 2022 Jan 31. Epub 2022 Jan 31.

Dermatology Unit, Ospedale Policlinico San Martino, Genoa, Italy. Electronic address:

Pityriasis rosea (PR), PR-like eruptions (PR-LE), and herpes zoster have been frequently reported during the COVID-19 pandemic and following COVID-19 vaccination. PR is a self-limiting exanthematous disease and herpes zoster is a treatable condition; therefore, their occurrence does not require discontinuation of the vaccination schedule. PR-LE is a hypersensitivity reaction and is, therefore, less predictable in its course. Read More

View Article and Full-Text PDF
January 2022

Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review.

J Formos Med Assoc 2022 May 5;121(5):1003-1007. Epub 2022 Jan 5.

Department of Pathology, En Chu Kong Hospital, New Taipei City, Taiwan.

Pityriasis rosea (PR) is a self-limited disease with exanthematous papulosquamous rashes mostly associated with reactivation of human herpesvirus (HHV)-6 or HHV-7. PR-like eruptions, which occur along with peripheral eosinophilia, interface dermatitis, and eosinophils on histopathology, may result from medications or vaccinations. Previously, PR-like eruptions had been noted following vaccination for influenza or other vaccines. Read More

View Article and Full-Text PDF

Comment on a case of pityriasis rosea shortly after Moderna COVID-19 vaccination.

Int J Infect Dis 2022 Mar 3;116:166. Epub 2022 Jan 3.

Dermatology Unit, Policlinico San Martino, Largo R. Benzi, 10, 16132 Genoa, Italy.

View Article and Full-Text PDF